Precision medicine company Macrogen announced on the 9th that its subsidiary, Somagen, will conduct a paid-in capital increase (general public offering) to raise 60.4 billion KRW. The funds will be allocated as follows: 13 billion KRW for debt repayment, 2.9 billion KRW for facility investment, and 7.5 billion KRW for operating expenses.



This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing